ANDLAUER HEALTHCARE GROUP IN (AND.CA) Fundamental Analysis & Valuation

TSX:AND • CA0342231077

Current stock price

54.97 CAD
+0.01 (+0.02%)
Last:

This AND.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. AND.CA Profitability Analysis

1.1 Basic Checks

  • AND had positive earnings in the past year.
  • AND had a positive operating cash flow in the past year.
  • Each year in the past 5 years AND has been profitable.
  • Each year in the past 5 years AND had a positive operating cash flow.
AND.CA Yearly Net Income VS EBIT VS OCF VS FCFAND.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • The Return On Assets of AND (9.81%) is better than 80.00% of its industry peers.
  • The Return On Equity of AND (15.35%) is better than 86.67% of its industry peers.
  • AND has a Return On Invested Capital of 11.76%. This is amongst the best in the industry. AND outperforms 86.67% of its industry peers.
  • AND had an Average Return On Invested Capital over the past 3 years of 11.97%. This is significantly above the industry average of 6.93%.
Industry RankSector Rank
ROA 9.81%
ROE 15.35%
ROIC 11.76%
ROA(3y)9.88%
ROA(5y)11.71%
ROE(3y)15.44%
ROE(5y)22.37%
ROIC(3y)11.97%
ROIC(5y)12.76%
AND.CA Yearly ROA, ROE, ROICAND.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • AND's Profit Margin of 10.37% is amongst the best of the industry. AND outperforms 86.67% of its industry peers.
  • In the last couple of years the Profit Margin of AND has remained more or less at the same level.
  • AND has a better Operating Margin (13.99%) than 86.67% of its industry peers.
  • AND's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of AND (33.85%) is worse than 60.00% of its industry peers.
  • AND's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 13.99%
PM (TTM) 10.37%
GM 33.85%
OM growth 3Y-4.81%
OM growth 5Y-1.42%
PM growth 3Y-21.44%
PM growth 5Y-0.72%
GM growth 3Y-14.76%
GM growth 5Y-10.42%
AND.CA Yearly Profit, Operating, Gross MarginsAND.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

8

2. AND.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AND is still creating some value.
  • Compared to 1 year ago, AND has less shares outstanding
  • The number of shares outstanding for AND has been increased compared to 5 years ago.
  • Compared to 1 year ago, AND has a worse debt to assets ratio.
AND.CA Yearly Shares OutstandingAND.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AND.CA Yearly Total Debt VS Total AssetsAND.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • AND has an Altman-Z score of 6.13. This indicates that AND is financially healthy and has little risk of bankruptcy at the moment.
  • AND has a Altman-Z score of 6.13. This is amongst the best in the industry. AND outperforms 93.33% of its industry peers.
  • The Debt to FCF ratio of AND is 1.80, which is an excellent value as it means it would take AND, only 1.80 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.80, AND belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • AND has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
  • AND's Debt to Equity ratio of 0.21 is amongst the best of the industry. AND outperforms 93.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 1.8
Altman-Z 6.13
ROIC/WACC1.44
WACC8.16%
AND.CA Yearly LT Debt VS Equity VS FCFAND.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.35 indicates that AND should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.35, AND belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
  • A Quick Ratio of 1.30 indicates that AND should not have too much problems paying its short term obligations.
  • The Quick ratio of AND (1.30) is better than 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.3
AND.CA Yearly Current Assets VS Current LiabilitesAND.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

4

3. AND.CA Growth Analysis

3.1 Past

  • AND shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.96%.
  • The Earnings Per Share has been growing by 14.82% on average over the past years. This is quite good.
  • The Revenue has been growing slightly by 0.34% in the past year.
  • AND shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.53% yearly.
EPS 1Y (TTM)1.96%
EPS 3Y-10.45%
EPS 5Y14.82%
EPS Q2Q%-10.53%
Revenue 1Y (TTM)0.34%
Revenue growth 3Y13.91%
Revenue growth 5Y17.53%
Sales Q2Q%-3%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.62% on average over the next years. This is quite good.
  • AND is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.95% yearly.
EPS Next Y6.54%
EPS Next 2Y10.13%
EPS Next 3Y8.62%
EPS Next 5YN/A
Revenue Next Year0.03%
Revenue Next 2Y1.88%
Revenue Next 3Y1.95%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AND.CA Yearly Revenue VS EstimatesAND.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
AND.CA Yearly EPS VS EstimatesAND.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

3

4. AND.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • AND is valuated quite expensively with a Price/Earnings ratio of 35.24.
  • Based on the Price/Earnings ratio, AND is valued a bit cheaper than 66.67% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.42, AND is valued a bit more expensive.
  • The Price/Forward Earnings ratio is 28.68, which means the current valuation is very expensive for AND.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AND indicates a somewhat cheap valuation: AND is cheaper than 73.33% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.24. AND is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 35.24
Fwd PE 28.68
AND.CA Price Earnings VS Forward Price EarningsAND.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AND is valued a bit cheaper than 66.67% of the companies in the same industry.
  • AND's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 21.69
EV/EBITDA 14.03
AND.CA Per share dataAND.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AND does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of AND may justify a higher PE ratio.
PEG (NY)5.39
PEG (5Y)2.38
EPS Next 2Y10.13%
EPS Next 3Y8.62%

3

5. AND.CA Dividend Analysis

5.1 Amount

  • AND has a yearly dividend return of 0.87%, which is pretty low.
  • Compared to an average industry Dividend Yield of 1.37, AND pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.81, AND's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.87%

5.2 History

  • The dividend of AND decreases each year by -34.89%.
  • AND has been paying a dividend for over 5 years, so it has already some track record.
  • AND has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-34.89%
Div Incr Years3
Div Non Decr Years3
AND.CA Yearly Dividends per shareAND.CA Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.1 0.2 0.3 0.4

5.3 Sustainability

  • AND pays out 26.73% of its income as dividend. This is a sustainable payout ratio.
DP26.73%
EPS Next 2Y10.13%
EPS Next 3Y8.62%
AND.CA Yearly Income VS Free CF VS DividendAND.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
AND.CA Dividend Payout.AND.CA Dividend Payout, showing the Payout Ratio.AND.CA Dividend Payout.PayoutRetained Earnings

AND.CA Fundamentals: All Metrics, Ratios and Statistics

ANDLAUER HEALTHCARE GROUP IN

TSX:AND (11/4/2025, 7:00:00 PM)

54.97

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-11
Earnings (Next)02-24
Inst Owners76.5%
Inst Owner ChangeN/A
Ins Owners2.53%
Ins Owner ChangeN/A
Market Cap2.15B
Revenue(TTM)650.58M
Net Income(TTM)67.49M
Analysts50
Price Target56.92 (3.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.87%
Yearly Dividend0.42
Dividend Growth(5Y)-34.89%
DP26.73%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.25%
Min EPS beat(2)-19.85%
Max EPS beat(2)-10.65%
EPS beat(4)0
Avg EPS beat(4)-9.2%
Min EPS beat(4)-19.85%
Max EPS beat(4)-0.99%
EPS beat(8)1
Avg EPS beat(8)-8.84%
EPS beat(12)3
Avg EPS beat(12)-6.41%
EPS beat(16)5
Avg EPS beat(16)11.49%
Revenue beat(2)0
Avg Revenue beat(2)-4.56%
Min Revenue beat(2)-7.25%
Max Revenue beat(2)-1.87%
Revenue beat(4)0
Avg Revenue beat(4)-3.59%
Min Revenue beat(4)-7.25%
Max Revenue beat(4)-1.87%
Revenue beat(8)1
Avg Revenue beat(8)-3.17%
Revenue beat(12)4
Avg Revenue beat(12)-1.94%
Revenue beat(16)7
Avg Revenue beat(16)0.32%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.43%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-6.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.5%
Valuation
Industry RankSector Rank
PE 35.24
Fwd PE 28.68
P/S 3.31
P/FCF 21.69
P/OCF 17.59
P/B 4.89
P/tB 17.04
EV/EBITDA 14.03
EPS(TTM)1.56
EY2.84%
EPS(NY)1.92
Fwd EY3.49%
FCF(TTM)2.53
FCFY4.61%
OCF(TTM)3.13
OCFY5.69%
SpS16.62
BVpS11.23
TBVpS3.23
PEG (NY)5.39
PEG (5Y)2.38
Graham Number19.8564 (-63.88%)
Profitability
Industry RankSector Rank
ROA 9.81%
ROE 15.35%
ROCE 16.09%
ROIC 11.76%
ROICexc 13.13%
ROICexgc 34.45%
OM 13.99%
PM (TTM) 10.37%
GM 33.85%
FCFM 15.25%
ROA(3y)9.88%
ROA(5y)11.71%
ROE(3y)15.44%
ROE(5y)22.37%
ROIC(3y)11.97%
ROIC(5y)12.76%
ROICexc(3y)12.48%
ROICexc(5y)13.78%
ROICexgc(3y)30.54%
ROICexgc(5y)29.2%
ROCE(3y)16.39%
ROCE(5y)17.47%
ROICexgc growth 3Y-1.36%
ROICexgc growth 5Y-1.14%
ROICexc growth 3Y4.48%
ROICexc growth 5Y-13.43%
OM growth 3Y-4.81%
OM growth 5Y-1.42%
PM growth 3Y-21.44%
PM growth 5Y-0.72%
GM growth 3Y-14.76%
GM growth 5Y-10.42%
F-Score5
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 1.8
Debt/EBITDA 0.56
Cap/Depr 32.65%
Cap/Sales 3.56%
Interest Coverage 250
Cash Conversion 75.6%
Profit Quality 147.02%
Current Ratio 1.35
Quick Ratio 1.3
Altman-Z 6.13
F-Score5
WACC8.16%
ROIC/WACC1.44
Cap/Depr(3y)36.55%
Cap/Depr(5y)30.34%
Cap/Sales(3y)3.8%
Cap/Sales(5y)3.06%
Profit Quality(3y)141.22%
Profit Quality(5y)125.45%
High Growth Momentum
Growth
EPS 1Y (TTM)1.96%
EPS 3Y-10.45%
EPS 5Y14.82%
EPS Q2Q%-10.53%
EPS Next Y6.54%
EPS Next 2Y10.13%
EPS Next 3Y8.62%
EPS Next 5YN/A
Revenue 1Y (TTM)0.34%
Revenue growth 3Y13.91%
Revenue growth 5Y17.53%
Sales Q2Q%-3%
Revenue Next Year0.03%
Revenue Next 2Y1.88%
Revenue Next 3Y1.95%
Revenue Next 5YN/A
EBIT growth 1Y-1.92%
EBIT growth 3Y8.43%
EBIT growth 5Y15.86%
EBIT Next Year74.49%
EBIT Next 3Y25.3%
EBIT Next 5YN/A
FCF growth 1Y6.06%
FCF growth 3Y11.81%
FCF growth 5Y13.66%
OCF growth 1Y-1.91%
OCF growth 3Y13.94%
OCF growth 5Y15.32%

ANDLAUER HEALTHCARE GROUP IN / AND.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ANDLAUER HEALTHCARE GROUP IN (AND.CA) stock?

ChartMill assigns a fundamental rating of 6 / 10 to AND.CA.


What is the valuation status of ANDLAUER HEALTHCARE GROUP IN (AND.CA) stock?

ChartMill assigns a valuation rating of 3 / 10 to ANDLAUER HEALTHCARE GROUP IN (AND.CA). This can be considered as Overvalued.


Can you provide the profitability details for ANDLAUER HEALTHCARE GROUP IN?

ANDLAUER HEALTHCARE GROUP IN (AND.CA) has a profitability rating of 7 / 10.


What are the PE and PB ratios of ANDLAUER HEALTHCARE GROUP IN (AND.CA) stock?

The Price/Earnings (PE) ratio for ANDLAUER HEALTHCARE GROUP IN (AND.CA) is 35.24 and the Price/Book (PB) ratio is 4.89.


What is the financial health of ANDLAUER HEALTHCARE GROUP IN (AND.CA) stock?

The financial health rating of ANDLAUER HEALTHCARE GROUP IN (AND.CA) is 8 / 10.